A RANDOMIZED PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN (TC) VERSUS PACLITAXEL PLUS CISPLATIN (TP) IN STAGE IVB OR RECURRENT CERVICAL CANCER: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0505)

被引：0
|
作者：
Kitagawa, R. [1 ]
Katsumata, N.
Shibata, T.
Nakanishi, T. [2 ]
Nishimura, S. [3 ]
Nishio, S. [4 ]
Takano, M. [5 ]
Satoh, T. [6 ]
Yokota, H. [7 ]
Ochiai, K. [8 ]
Kigawa, J. [9 ]
Kobayashi, H. [10 ]
Kanato, K. [11 ]
Yoshikawa, H. [6 ]
Kamura, T. [4 ]
机构：
[1] NTT Med Ctr Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Gynecol Oncol, Aichi, Japan
[3] Osaka City Gen Hosp, Dept Gynecol Oncol, Osaka, Japan
[4] Kurume Univ, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan
[5] Natl Def Med Coll Hosp, Dept Obstet & Gynecol, Tokorozawa, Saitama, Japan
[6] Univ Tsukuba, Dept Obstet & Gynecol, Tsukuba, Ibaraki 305, Japan
[7] Saitama Canc Ctr, Dept Gynecol Oncol, Saitama, Japan
[8] Jikei Univ, Dept Obstet & Gynecol, Tokyo, Japan
[9] Tottori Univ, Dept Obstet & Gynecol, Yonago, Tottori, Japan
[10] Kyushu Univ, Dept Obstet & Gynecol, Fukuoka 812, Japan
[11] Natl Canc Ctr, Multiinst Clin Trial Support Ctr, JCOG Operat Off, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [41] Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study
    Gallion, HH
    Brunetto, VL
    Cibull, M
    Lentz, SS
    Reid, G
    Soper, JT
    Burger, RA
    Andersen, W
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3808 - 3813
  • [42] Phase II randomized trial of cisplatin/paclitaxel plus lonidamine versus cisplatin/ifosfamide plus lonidamine in the treatment of ovarian cancer.
    Lorusso, V
    Calabrese, R
    Latorre, A
    Guida, M
    Misino, A
    Spada, M
    Paradiso, A
    De Lena, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 879S - 879S
  • [43] Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
    Markman, M
    Bundy, BN
    Alberts, DS
    Fowler, JM
    Clark-Pearson, DL
    Carson, LF
    Wadler, S
    Sickel, J
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 1001 - 1007
  • [44] A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
    Treat, J. A.
    Gonin, R.
    Socinski, M. A.
    Edelman, M. J.
    Catalano, R. B.
    Marinucci, D. M.
    Ansari, R.
    Gillenwater, H. H.
    Rowland, K. M.
    Comis, R. L.
    Obasaju, C. K.
    Belani, C. P.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 540 - 547
  • [45] Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
    Thongprasert, Sumitra
    Permsuwan, Unchalee
    Ruengorn, Chidchanok
    Charoentum, Chaiyut
    Chewaskulyong, Busyamas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (04) : 369 - 375
  • [46] Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
    Burtness, B
    Goldwasser, MA
    Flood, W
    Mattar, B
    Forastiere, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8646 - 8654
  • [47] Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)
    Mizusawa, Junki
    Morizane, Chigusa
    Okusaka, Takuji
    Katayama, Hiroshi
    Ishii, Hiroshi
    Fukuda, Haruhiko
    Furuse, Junji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (04) : 385 - 388
  • [48] Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial
    Chen, Yun
    Ye, Jinjun
    Zhu, Zhengfei
    Zhao, Weixin
    Zhou, Jialiang
    Wu, Chaoyang
    Tang, Huarong
    Fan, Min
    Li, Ling
    Lin, Qin
    Xia, Yi
    Li, Yunhai
    Li, Jiancheng
    Jia, Huixun
    Lu, Saiquan
    Zhang, Zhen
    Zhao, Kuaile
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (20) : 1695 - +
  • [49] Toxicity analysis of SWOG 9509: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated patients with advanced non-small cell lung cancer (NSCLC). A Southwest Oncology Group Trial
    Kelly, K
    Crowley, J
    Bunn, PA
    Livingston, RB
    Gandara, DR
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 24 - 24
  • [50] A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100)
    Miller, KD
    Wang, M
    Gralow, J
    Dickler, M
    Cobleigh, MA
    Perez, EA
    Shenkier, TN
    Davidson, NE
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S6 - S6
12345